The present invention is directed to squaraine fluorophores, methods of making squaraine fluorophores, and methods of using squaraine fluorophores. In some embodiments, squaraine fluorophores can be used as imaging agents, for example for imaging cancer. In some embodiments, the squaraine fluorophores can be used to guide surgical tumor resection.

The invention provides a novel process for manufacturing a compound of formula (I), or a salt thereof,

##STR00001##

wherein PG.sup.1, PG.sup.2 and PG.sup.3 are amino protective groups. The process according to the invention is particularly suitable for large-scale manufacturing under GMP conditions.

The invention provides a novel process for manufacturing a compound of formula (I), or a salt thereof,

##STR00001##

wherein PG.sup.1, PG.sup.2 and PG.sup.3 are amino protective groups. The process according to the invention is particularly suitable for large-scale manufacturing under GMP conditions.

The invention provides compositions and methods for wound healing and scar reduction. The compositions and methods of the invention include at least one EP4 agonist set forth herein. Wounds and or scars that can be treated by the compositions and methods of the invention can arise from events such as surgery, trauma, disease, mechanical injury, burn, radiation, poisoning, and the like.

The invention provides compositions and methods for wound healing and scar reduction. The compositions and methods of the invention include at least one EP4 agonist set forth herein. Wounds and or scars that can be treated by the compositions and methods of the invention can arise from events such as surgery, trauma, disease, mechanical injury, burn, radiation, poisoning, and the like.

The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y.sub.1 receptor which may be used medicaments. ##STR00001##

The present invention provides compounds of Formula (I): Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are antagonists of P2Y.sub.1 receptor which may be used medicaments. ##STR00001##

Disclosed are compounds of formula (I), wherein ring A is an 8-10 membered aromatic or partially aromatic bicyclic ring having 1-4 heteroatoms compositions thereof, wherein L1, L2, R1 to R4 and m are as defined in claim 1; and methods of using the same for antagonizing G-protein coupled receptor OXER1, and for treating of OXER1-mediated disorders, such as asthma or cancer.

##STR00001##

Disclosed are compounds of formula (I), wherein ring A is an 8-10 membered aromatic or partially aromatic bicyclic ring having 1-4 heteroatoms compositions thereof, wherein L1, L2, R1 to R4 and m are as defined in claim 1; and methods of using the same for antagonizing G-protein coupled receptor OXER1, and for treating of OXER1-mediated disorders, such as asthma or cancer.

##STR00001##

There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and/or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided. ##STR00001##